Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc. (MNPR) is a clinical-stage biopharmaceutical company whose news flow centers on drug development milestones, scientific data presentations, financial updates, and capital markets activity. Public communications describe a focus on late-stage ALXN1840 for Wilson disease and MNPR-101-based radiopharmaceutical programs for imaging and treating advanced cancers.
News items for Monopar commonly include clinical and scientific results, such as data from the ALXN1840-WD-204 copper balance study and pooled long-term neurological and safety analyses in Wilson disease. The company also reports on presentations at major medical meetings, including the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting and the American Neurological Association (ANA) Annual Meeting, as well as publications in peer-reviewed journals like the Journal of Hepatology.
Investors and observers can also find updates on radiopharmaceutical programs, including progress in Phase 1 imaging and therapeutic trials with MNPR-101-Zr and MNPR-101-Lu, and regulatory developments such as U.S. Food and Drug Administration authorization for an Expanded Access Program in advanced solid tumors. In addition, Monopar issues press releases on financial results, describing quarterly performance, research and development spending, and general and administrative expenses, alongside information on cash resources and capital-raising transactions.
Further topics in Monopar’s news include capital markets events, such as underwritten offerings of common stock and pre-funded warrants, share repurchase agreements with existing stockholders, and inclusion in the Russell 3000 and Russell 2000 indexes. Readers interested in MNPR news can use this page to follow these developments and review how the company describes the evolution of its Wilson disease and radiopharmaceutical programs over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced that Dr. Chandler Robinson, the CEO, will present at the Jefferies Radiopharma Innovation Summit on April 3, 2023, from 1:00 to 1:30 pm at the Jefferies Conference Center in NYC.
The company focuses on developing therapeutics aimed at extending life and improving the quality of life for cancer patients. Their pipeline includes camsirubicin (Phase 1b) for advanced soft tissue sarcoma and MNPR-101 for radiopharmaceutical use in advanced cancers. Monopar is committed to enhancing cancer patient care through innovation.